Abstract:Chemotherapeutics have been recommended as the standard protocol for inoperable patients with triple -negative breast cancer (TNBC) at advanced stage, yet limited success has been achieved in prolonging sur-vival rates by this monotherapy. A major reason for this failure is the chemo-resistance from traditional apoptotic pathways resulting in poor therapeutic effect. Ferroptosis has become a powerful modality of no-apoptotic cell death, which can effectively evade chemo-resistance in apoptotic pathways. Herein, we propose an active-targeting small-molecular self-assembly nano-prodrug for co-delivery of chemother-apeutics (CPT), Ferrocene (Fc) and GPX4 inhibitor (RSL3) to overcome the chemo-resistance from tradi-tional apoptotic pathways. In this nano-prodrug, the disulfide linkage not only serves as a GSH-responsive trigger, but also exhibits a stable self-assembly behavior that forms nanoparticle. Interestingly, the RSL3 can be loaded during this self-assembly process that forms a three-components nano-prodrug. In tumor environment, the high GSH level can disassemble the nano-prodrug to trigger the release of the parent drug, which can improve the therapeutic effect by synergistic effects of ferroptosis and apoptosis. In dif-ferent TNBC mice models, the nano-prodrug is encapsulated into RGD-modified phospholipid micelles (DSPE-PEG20 0 0-RGD) and exhibits high anti-tumor and anti-metastasis efficacy, especially in orthotopic models. The application of ferroptosis to assist the enhancement of chemotherapeutics may serve as a promising strategy for TNBC treatment.Statement of significanceChemotherapeutics have been recommended as the standard of care for palliative and adjuvant treatment in patients with triple-negative breast cancer (TNBC), yet limited success has been achieved in prolong-ing the overall survival of patients by this monotherapy. A major reason for this failure is the chemo-resistance from traditional apoptotic pathways resulting in poor therapeutic effect. Thus, the co-delivery of the apoptosis and ferroptosis drug may overcome or evade the resistance in chemotherapy-induced apoptotic pathways and provide a promising strategy to combat TNBC. In this work, we developed a small-molecular self-assembly nano-prodrug for co-delivery of chemotherapeutics (CPT), Ferrocene (Fc) and ferroptosis resistance inhibitor (RSL3), which could overcome the chemo-resistance and improve the therapeutic effect by synergistic effects of ferroptosis and apoptosis.(c) 2023 Acta Materialia Inc. Published by Elsevier Ltd. All rights reserved.

Platinum prodrug nanoparticles inhibiting tumor recurrence and metastasis by concurrent chemoradiotherapy

Nanoparticle Delivery of a Triple-Action Pt(iv) Prodrug to Overcome Cisplatin Resistance Via Synergistic Effect

A Nanomedicine Based on Stoichiometric Coordination of Camptothecin and Organoplatinum (II) for Synergistic Antitumor Therapy.

Platinum Nanoparticles to Enable Electrodynamic Therapy for Effective Cancer Treatment.

Targeting Ferroptosis with Polymerized Platinum (IV) Prodrugs Nanoparticles with Everolimus for Enhancing Therapeutic Efficacy on Cholangiocarcinoma

A Fe(III)-porphyrin-oxaliplatin(IV) Nanoplatform for Enhanced Ferroptosis and Combined Therapy

Cancer cell membrane-camouflaged CuPt nanoalloy boosts chemotherapy of cisplatin prodrug to enhance anticancer effect and reverse cisplatin resistance of tumor

Overcoming Radiation Resistance by Iron-Platinum Metal Alloy Nanoparticles in Human Copper Transport 1-Overexpressing Cancer Cells via Mitochondrial Disturbance

A Self-Assembly Nano-Prodrug for Triple-Negative Breast Cancer Combined Treatment by Ferroptosis Therapy and Chemotherapy

Self-amplifying ROS-sensitive SN38 Dimeric Prodrug nanoparticles for Combined Chemotherapy and Ferroptosis in Cancer Treatment

Platinum Drug‐Incorporating Polymeric Nanosystems for Precise Cancer Therapy

A Dual Stimuli‐responsive Nanoplatform Loaded PtIV‐triptolide Prodrug for Achieving Synergistic Therapy Toward Breast Cancer

Metal-Polyphenol-Network Coated Prussian Blue Nanoparticles for Synergistic Ferroptosis and Apoptosis Via Triggered GPX4 Inhibition and Concurrent in Situ Bleomycin Toxification.

Sequential dual-locking strategy using photoactivated Pt(IV)-based metallo-nano prodrug for enhanced chemotherapy and photodynamic efficacy by triggering ferroptosis and macrophage polarization

In-situ oxidative polymerization of platinum(IV) prodrugs in pore-confined spaces of CaCO3 nanoparticles for cancer chemoimmunotherapy

Blood-triggered Generation of Platinum Nanoparticle Functions As an Anti-Cancer Agent

Biocompatible Nanoparticles as a Platform for Enhancing Antitumor Efficacy of Cisplatin-Tetradrine Combination

Reduction-sensitive platinum (IV)-prodrug nano-sensitizer with an ultra-high drug loading for efficient chemo-radiotherapy of Pt-resistant cervical cancer in vivo

A Metal–Polyphenol‐Coordinated Nanomedicine for Synergistic Cascade Cancer Chemotherapy and Chemodynamic Therapy

Transferrin-Modified Carprofen Platinum(IV) Nanoparticles as Antimetastasis Agents with Tumor Targeting, Inflammation Inhibition, Epithelial-Mesenchymal Transition Suppression, and Immune Activation Properties

Mesoporous Platinum Nanotherapeutics For Combined Chemo-Photothermal Cancer Treatment